Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Longitudinal one-year stu… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.

Artikel i vetenskaplig tidskrift
Författare Axel Petzold
Edward J Thompson
Geoffrey Keir
Niall Quinn
Björn Holmberg
Nil Dizdar
Gregor K Wenning
Olivier Rascol
Eduardo Tolosa
Lars Rosengren
Publicerad i Journal of the neurological sciences
Volym 279
Nummer/häfte 1-2
Sidor 76-9
ISSN 1878-5883
Publiceringsår 2009
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Sidor 76-9
Språk en
Länkar dx.doi.org/10.1016/j.jns.2008.12.03...
Ämnesord Adult, Aged, Aged, 80 and over, Biological Markers, cerebrospinal fluid, Disease Progression, Enzyme-Linked Immunosorbent Assay, Female, Human Growth Hormone, biosynthesis, therapeutic use, Humans, Linear Models, Longitudinal Studies, Male, Middle Aged, Multiple System Atrophy, cerebrospinal fluid, drug therapy, Neurofilament Proteins, cerebrospinal fluid, Neuroprotective Agents, therapeutic use, Recombinant Proteins, therapeutic use
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

BACKGROUND: Two cerebrospinal fluid (CSF) biomarkers specific for neurodegeneration have recently emerged - the neurofilament light (NfL, 68 kDa) and heavy (NfH, 190-210 kDa) chains. This study investigated whether the CSF NfH and NfL levels or their stoichiometric relationship changed over time in a neuroprotective treatment trial. METHODS: Serial CSF samples (n=95) from 42 patients with multiple system atrophy (MSA), half randomized to treatment with recombinant human growth hormone (r-hGH) and the other half to placebo, were collected at baseline, 6 and 12 months. The concentration of CSF NfL and NfH was determined using standard ELISAs. RESULTS: There was no consistent change in the levels of either protein over the 12 month period, or between treatment with active r-hGH versus placebo. The molar stoichiometry of CSF NfL:NfH was 4:1 (R=0.37, p=0.0002) and increased following treatment with r-hGH (p=0.03). CONCLUSION: These results indicate that CSF levels of both NfL and NfH on their own are not useful markers of disease progression in MSA, at least over a 12-month period. Future work is needed to elucidate whether the CSF stoichiometry and dynamics of Nf subunits in individual patients are a feature of the underlying pathology and of diagnostic or prognostic value.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?